RASSF9 and esophageal squamous cell carcinoma: As previously reported, using co-immunoprecipitation coupled with mass spectrometry (MS/MS), we identified RASSF9 as a downstream target of TAK1 to repress on cell proliferation in ESCC (Shi et al., 2021).